Arbutus Biopharma (ABUS) to Release Earnings on Thursday

Arbutus Biopharma (NASDAQ:ABUS) will be issuing its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings data on Thursday, February 29th. The biopharmaceutical company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Arbutus Biopharma had a negative net margin of 401.57% and a negative return on equity of 57.82%. The company had revenue of $2.15 million during the quarter, compared to the consensus estimate of $4.74 million. During the same quarter last year, the firm posted ($0.14) EPS. On average, analysts expect Arbutus Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Arbutus Biopharma Stock Up 1.8 %

Arbutus Biopharma stock opened at $2.78 on Tuesday. The company has a market capitalization of $498.98 million, a PE ratio of -6.32 and a beta of 2.04. The firm’s fifty day moving average is $2.76 and its 200 day moving average is $2.38. Arbutus Biopharma has a 12-month low of $1.69 and a 12-month high of $3.29.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. JMP Securities reissued a “market outperform” rating and set a $4.00 price objective on shares of Arbutus Biopharma in a research report on Thursday, April 4th. HC Wainwright cut their price target on Arbutus Biopharma from $6.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, March 1st. Finally, Chardan Capital restated a “buy” rating and set a $4.00 price objective on shares of Arbutus Biopharma in a report on Friday, March 1st.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.